28.07.2013 Views

Dave Forsey Chief Executive 19 July 2012 - Sports Direct International

Dave Forsey Chief Executive 19 July 2012 - Sports Direct International

Dave Forsey Chief Executive 19 July 2012 - Sports Direct International

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Employee Benefit Trust<br />

The cost of shares acquired by the <strong>Sports</strong> <strong>Direct</strong> Employee Benefit<br />

Trust is recognised within ‘Own share reserve’ in equity.<br />

Share based payments<br />

The Group issues equity-settled share-based payments to certain<br />

directors and employees. These are measured at fair value at<br />

the date of grant, which is expensed to the consolidated income<br />

statement on a straight-line basis over the vesting period, with the<br />

corresponding credit going to equity.<br />

Non-market vesting conditions are not taken into account in<br />

determining grant date fair value. Instead, they are taken into<br />

account by adjusting the number of equity instruments to vest.<br />

Fair value is based on the market share price on the grant date, the<br />

likelihood of meeting the vesting targets and the expected number<br />

of staff who will leave the Company prior to the vesting date. The<br />

expected staff numbers used in the model has been adjusted,<br />

based on management’s best estimate, for the effects of nontransferability,<br />

exercise restrictions, and behavioural considerations.<br />

A share-based payment charge of £20,643,000 was recognised<br />

in selling, distribution and administrative expenses for the 53<br />

weeks ended 29 April <strong>2012</strong>. The key details in respect of the share<br />

scheme charges are set out in Note 21.<br />

Equity instruments<br />

An equity instrument is any contract that evidences a residual<br />

interest in the assets of the Group after deducting all of its liabilities.<br />

Equity instruments issued by the Group are recorded at the<br />

proceeds received, net of any direct issue costs.<br />

Dividends<br />

Dividends are recognised as a liability in the Group’s financial<br />

statements and as a deduction from equity in the period in which<br />

the dividends are declared. Where such dividends are proposed<br />

subject to the approval of shareholders, the dividends are regarded<br />

as declared once shareholder approval has been obtained.<br />

2. Critical accounting estimates and judgements<br />

The critical accounting estimates and judgements<br />

made by the Group regarding the future or other key<br />

sources of estimation, uncertainty and judgement that<br />

may have a significant risk of giving rise to a material<br />

adjustment to the carrying values of assets and<br />

liabilities within the next financial year are:<br />

Impairment of goodwill<br />

The calculation for considering the impairment of the carrying<br />

amount of goodwill requires a comparison of the present value of<br />

the cash-generating units to which the goodwill has been allocated,<br />

to the value of goodwill and associated assets in the balance sheet.<br />

The calculation of present values requires an estimation of the future<br />

cash flows expected to arise from the cash-generating units and<br />

the selection of a suitable discount rate.<br />

The key assumptions made in relation to the impairment review of<br />

goodwill are set out in Note 15.<br />

<strong>International</strong> Financial Reporting Standards (“Standards”) in<br />

issue but not yet effective<br />

At the date of authorisation of these consolidated financial<br />

statements, the <strong>International</strong> Accounting Standards Board (“IASB”)<br />

and <strong>International</strong> Financial Reporting Standards Committee<br />

(“IFRSC”) have issued the following standards and interpretations<br />

which are effective for annual accounting periods beginning on or<br />

after the stated effective date.<br />

These standards and interpretations are not effective for and have<br />

not been applied in the preparation of the consolidated financial<br />

statements:<br />

• IFRS 9 Financial Instruments (effective 1 January 2015)<br />

• IFRS 10 Consolidated Financial Statements<br />

(effective 1 January 2013)<br />

• IFRS 11 Joint arrangements (effective 1 January 2013)<br />

• IFRS 12 Disclosures Of Interest in Other Entities<br />

(effective 1 January 2013)<br />

• IFRS 13 Fair Value Measurement (effective 1 January 2013)<br />

• IAS 27 (Revised), Separate Financial Statements<br />

(effective 1 January 2013)<br />

• IAS 28 (Revised), Investments in Associates and Joint Ventures<br />

(effective 1 January 2013)<br />

• Deferred Tax: Recovery of Underlying Assets - Amendments to<br />

IAS 12 Income Taxes (effective 1 January <strong>2012</strong>)<br />

• Annual Improvements 2009-2011 Cycle<br />

(effective 1 January 2013)<br />

The directors anticipate that the adoption of these standards and<br />

interpretations in future periods will have no material impact on the<br />

financial statements of the Group except for the treatment of the<br />

acquisition of subsidiaries in future accounting periods.<br />

Impairment of tangible assets<br />

The directors review the carrying amounts of the Group’s tangible<br />

assets to determine whether there is any indication that those<br />

assets have suffered an impairment loss. The key assumptions<br />

made in relation to the impairment review of tangible assets are set<br />

out in Note 16.<br />

Impairment of other intangible assets<br />

The calculation for considering the impairment of the carrying<br />

amount of other intangible assets with an indefinite life, specifically<br />

brands, trade marks and licences, requires a comparison of the<br />

present value of the related cash flows to the value of the other<br />

intangible assets in the balance sheet. The calculation of present<br />

value requires an estimation of the future cash flows expected<br />

to arise from the other intangible assets and the selection of a<br />

suitable discount rate. The key assumptions made in relation to the<br />

impairment review of other intangible assets are set out in Note 15.<br />

77

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!